SCHEMBL3591348

SCHEMBL3591348

FC(F)(F)c1nc2ccccc2n1-c1nc(Cl)cc(N2CCOCC2)n1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 12/20 0.71
ATR Q13535 2/20 0.51
CHEK1 O14757 1/20 0.51
PDCD1 Q15116 1/20 0.51
ATRIP Q8WXE1 1/20 0.51
CD274 Q9NZQ7 1/20 0.51
PIK3CA P42336 5/20 0.48
PIK3CD O00329 4/20 0.48
PIK3CG P48736 4/20 0.48
PIK3R1 P27986 2/20 0.48
PIK3C2B O00750 1/20 0.48
MTOR P42345 1/20 0.48
MAPK1 P28482 1/20 0.48
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4572977 0.92 PIK3CB (0.73) PIK3CBATRCHEK1PDCD1ATRIP
SCHEMBL4306313 0.84 PIK3CB (0.67) PIK3CBATRCHEK1PDCD1ATRIP
SCHEMBL948460 0.83 PIK3CB (0.85) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
Hydrochloric Acid SCHEMBL3598484 0.83 PIK3CB (0.66) PIK3CBATRCHEK1PDCD1ATRIP
SCHEMBL4528139 0.80 PIK3CB (0.63) PIK3CBATRCHEK1PDCD1ATRIP
SCHEMBL4573169 0.78 PIK3CB (0.81) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL29434923 0.78 PIK3CB (0.81) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL3583966 0.77 PIK3CB (0.54) PIK3CBATRCHEK1PDCD1ATRIP
SCHEMBL3583967 0.76 PIK3CB (0.56) PIK3CBATRCHEK1PDCD1ATRIP
SCHEMBL3599705 0.76 PIK3CB (0.66) PIK3CBATRCHEK1PDCD1ATRIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022534-A1 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA (GB) 2010-01-28 US disclosed
US-20090325954-A1 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-12-31 US disclosed
CN-101595103-A Pyrimidine derivatives ASTRAZENECA AB (SE) 2009-12-02 CN disclosed
US-20090270390-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA (SE) 2009-10-29 US disclosed
CN-101563339-A 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or aza ) pyrimidine derivatives as P I3K and MtToR inhibitors for the treatment of proliferative diseases ASTRAZENECA AB (SE) 2009-10-21 CN disclosed
CN-101535296-A 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders ASTRAZENECA AB (SE) 2009-09-16 CN disclosed
EP-2069330-A1 2 -BENZIMIDAZOLYL- 6 -MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2009-06-17 EP disclosed
EP-2061784-A1 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2009-05-27 EP disclosed
EP-2057147-A1 PYRIMIDINE DERIVATIVES Astra Zeneca AB (SE) 2009-05-13 EP disclosed
WO-2008032064-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2008-03-20 WO disclosed
WO-2008032028-A1 2 -BENZIMIDAZOLYL- 6 -MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2008-03-20 WO disclosed
WO-2008032086-A1 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325954-A1 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS PIK3CA, MTOR, PIK3CD PIK3CB 4/4885ATR 933/4885CHEK1 117/4885
US-20100022534-A1 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS MTOR, PIK3CA, PIK3CD PIK3CB 13/4885ATR 307/4885CHEK1 115/4885
US-20090270390-A1 PYRIMIDINE DERIVATIVES TYMP, DPYD, TYMS PIK3CB 1101/4885ATR 670/4885CHEK1 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.